Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 4, 2012, Pages 387-393

  Menas, Pamela ^a   Merkel, Douglas ^a   Hui, Wendy ^a   Lawton, Jessica ^a   Harper, Abigail ^a   Carro, George ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Aromatase inhibitors; arthralgias; breast cancer

Indexed keywords

ALPHA TOCOPHEROL; ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM; CHONDROITIN; EXEMESTANE; FISH OIL; GLUCOSAMINE; HORMONE RECEPTOR; HYDROCODONE; IBUPROFEN; LETROZOLE; LINSEED OIL; NAPROXEN; PARACETAMOL; VITAMIN D;

ADULT; ALGORITHM; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT DEPARTMENT; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; YOGA;

ANDROSTADIENES; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; OUTPATIENTS; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84865370844     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211434853     Document Type: Review

References (13)

1. American Cancer Society. 'How many women get breast cancer?', http://www.cancer.org (accessed June 2011).
2. WebMD. 'Types of breast cancer: ER Positive, HER2 positive, and triple negative', http://www.webmd.com/breast-cancer/breast-cancer-types-er-positive- her2-positive (accessed April 2010).
3. Sehdev S, Martin G, Sideris L, et al. Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Curr Oncol. 2009 ; 16 (Suppl 2). S14 - S23
4. Morales L, Pans S, Verschueren K, et al. Perspective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008 ; 26: 3147-3152
5. Coleman R, Bolten W, Lansdown M, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendation. Cancer Treat Rev. 2008 ; 34: 275-282
6. Hershman D. Getting a grip on aromatase inhibitor-associated arthralgias. J Clin Oncol. 2008 ; 26: 3120-3121
7. Mao J, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009 ; 115: 3631-3639
8. Crew K, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in post menopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007 ; 25: 3877-3883
9. Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008 ; 9: 866-872
10. Hess D. Retrospective studies and chart reviews. Respir Care. 2004 ; 49 (10). 1171-1174
11. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post menopausal women with early breast cancer: first results of the ATAC randomized trial. The Lancet. 2002 ; 349 (9324). 2131-2139
12. Cuzick J, Sestak I, Cella D, et al. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008 ; 9: 1143-1148
13. CTCAE. Common terminology criteria for adverse events v 3.0, National Institutes of Health, National Cancer Institute, August 2006.